Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study.
(2013) Leukemia Research Reports — Vol. 2, n° 2, p. 64-66 (2013)
Files
document.pdf
Open Access - Adobe PDF
- 287.41 KB
Details
- Authors
- Abstract
- While in RARS-T, JAK2V617F mutation is common and associated with good prognosis, the clinical and prognostic impact of this mutation in other MDS is unknown. We collected data from 132 non-RARS-T MDS with known JAK2V617F mutation status. JAK2V617F mutation was significantly correlated with lower progression to AML (p<.0011) and better overall survival (OS, p=.011). OS difference persisted after matching on age, sex, IPSS and % marrow blast (p=.031). Thus, in MDS other than RARS-T, JAK2V617F mutation may be associated with favorable outcome.
- Affiliations
Citations
de Renzis, B., Mansat-De Mas, V., Wattel, E., Beyne-Rauzy, O., Knoops, L., Cabrespine, A., Azgui, Z., Ades, L., Kiladjian, J.-J., & Fenaux, P. (2013). Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study. Leukemia Research Reports, 2(2), 64-66. https://doi.org/10.1016/j.lrr.2013.06.003 (Original work published 2013)